THE USAGE OF ACALABRUTINIB IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
Acalabrutinib is highly effective in chronic lymphocytic leukemia treatment. Its mechanism of action is more selective that in previous generation representative - ibrutinib, and depends on inhibition of Bruton thyrosinekinase - the main element in signal transmission by BCR receptors of affected B-lymphocytes. The drug is of great interest in combined native or relasapsed/refractory chronic lymphocytic leukemia therapy. In result of many clinical investigations acalabtutinib reflected a significant efficiency level: higher meanings of progression-free survival, higher frequency of therapy response and lower number of side effects in comparison with chemotherapy (chlorambucil, fludarabine, cyclophosphamide, etc.). In particular, the by-effects of acalabrutinib included atrial fibrillation, bleeding of any grade, neutropenia, diarrhea, cough, nausea, accession of secondary infection and appearance of one more kind of cancer. The side effects for ibrutinib are the same as well too. But acalabrutinib's frequency of complications is lower comparable to ibrutinib's in percentage of atrial fibrillation (3% and 6% respectively) and serious bleeding (3% and 8%), and less leads to disconnection of treatment. Described characteristics serve as recommendations of acalabrutinib first line treatment in the chronic lymphocytic leukemia therapy.